Related Experiment Video
Updated: May 30, 2026
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy
Daniel P Judge1, David A Kass, W Reid Thompson
1Division of Cardiology/Medicine, Johns Hopkins University, Baltimore, MD 21205, USA. djudge@jhmi.edu
Insights
Duchenne muscular dystrophy (DMD) causes heart problems like dilated cardiomyopathy. New research explores targeted treatments beyond standard care, focusing on molecular pathways to improve cardiac function in DMD patients.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Cardiac dysfunction, including dilated cardiomyopathy (DCM), is a major cause of death in Duchenne muscular dystrophy (DMD).
- While respiratory support has improved lifespan, heart failure and sudden death remain critical issues for DMD patients.
- Current treatments for DMD-associated cardiomyopathy are standard DCM approaches, as underlying mechanisms are not fully understood.
Purpose of the Study:
- To review the mechanisms of cardiac dysfunction in DMD.
- To identify potential pharmacologic targets for preventing or treating DMD-associated cardiomyopathy.
- To discuss novel therapeutic strategies beyond current standard care.
Main Methods:
- Review of existing literature on DMD cardiomyopathy.
- Analysis of molecular pathways involved in dystrophin deficiency and cardiac function.
- Discussion of emerging therapeutic targets such as PDE5 inhibitors.
Main Results:
- DMD cardiomyopathy involves early diastolic dysfunction and fibrosis, progressing to DCM.
- Standard treatments like ACE inhibitors and beta-blockers are used, with evidence supporting early ACE inhibitor use.
- Novel targets include the roles of dystrophin, nNOS, and TRPC channels, with promising results for PDE5 inhibitors in preclinical models.
Conclusions:
- Understanding DMD cardiomyopathy mechanisms is crucial for developing targeted therapies.
- Novel pharmacologic targets, particularly those related to dystrophin function and PDE5 inhibition, show potential for improving cardiac outcomes in DMD.
- Further investigation and clinical trials are needed to validate these novel approaches.
Abstract:
Cardiac dysfunction is a frequent manifestation of Duchenne muscular dystrophy (DMD) and a common cause of death for individuals with this condition. Early diastolic dysfunction and focal fibrosis proceed to dilated cardiomyopathy (DCM), complicated by heart failure and arrhythmia in most patients. Improvements in the management of respiratory insufficiency in DMD have improved lifespan and overall prognosis, but heart failure and sudden death continue to impact survival and quality of life for people with DMD. Since the specific mechanisms resulting in heart failure for people with DMD are poorly understood, current treatments are not targeted, but rely on approaches that are considered standard for DCM. These approaches include angiotensin-converting enzyme (ACE) inhibitors and β-adrenoceptor antagonists. Data from one trial in DMD support the use of ACE inhibitors before the onset of left ventricular dysfunction. Angiotensin receptor blockers have shown similar efficacy to ACE inhibitors in numerous studies of dilated cardiomyopathy, and are a good choice for patients who cannot tolerate ACE inhibition. The pathogenesis of DMD-associated cardiomyopathy may be similar to other genetic disorders of the cytoskeletal complex of ventricular myocytes, though unique features offer targeted opportunities to impact treatment. Novel areas of investigation are focused on the regulatory role of dystrophin in relation to neuronal nitric oxide synthase (nNOS) and transient receptor potential canonical channels (TRPC). Inhibition of phosphodiesterase-5 (PDE5) addresses several aspects of regulatory dysfunction induced by dystrophin deficiency, and studies with PDE5-inhibitors have shown benefits in murine models of DMD. PDE5-inhibitors are currently under investigation in at least one study in humans. This article focuses on mechanisms of cardiac dysfunction, as well as potential targets for pharmacologic manipulation to prevent or improve cardiomyopathy in DMD.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:21Satellite Stem Cells and Muscular Dystrophy
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:17Pathophysiology of Heart Failure
01:29Heart Failure II: Pathophysiology